Pacer Advisors Inc. boosted its position in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 20.5% in the second quarter, Holdings Channel reports. The fund owned 4,882 shares of the medical equipment provider’s stock after acquiring an additional 830 shares during the period. Pacer Advisors Inc.’s holdings in ABIOMED were worth $1,272,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in ABMD. Geode Capital Management LLC lifted its position in ABIOMED by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 606,848 shares of the medical equipment provider’s stock worth $196,924,000 after acquiring an additional 32,418 shares during the last quarter. Candriam Luxembourg S.C.A. increased its holdings in shares of ABIOMED by 24.4% during the 1st quarter. Candriam Luxembourg S.C.A. now owns 3,761 shares of the medical equipment provider’s stock worth $1,074,000 after purchasing an additional 737 shares during the period. Cornerstone Advisors Inc. increased its holdings in shares of ABIOMED by 94.1% during the 1st quarter. Cornerstone Advisors Inc. now owns 165 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 80 shares during the period. California Public Employees Retirement System increased its holdings in shares of ABIOMED by 0.8% during the 1st quarter. California Public Employees Retirement System now owns 72,818 shares of the medical equipment provider’s stock worth $20,796,000 after purchasing an additional 597 shares during the period. Finally, Mn Services Vermogensbeheer B.V. increased its holdings in shares of ABIOMED by 1.7% during the 1st quarter. Mn Services Vermogensbeheer B.V. now owns 23,368 shares of the medical equipment provider’s stock worth $6,674,000 after purchasing an additional 400 shares during the period. 91.53% of the stock is owned by hedge funds and other institutional investors.

Several research analysts have recently issued reports on the stock. Guggenheim downgraded shares of ABIOMED from a “buy” rating to a “neutral” rating in a report on Friday, August 2nd. William Blair restated a “buy” rating on shares of ABIOMED in a report on Friday, August 2nd. BTIG Research downgraded shares of ABIOMED from a “buy” rating to a “neutral” rating in a report on Thursday, August 1st. TheStreet downgraded shares of ABIOMED from a “b-” rating to a “c+” rating in a report on Thursday, August 22nd. Finally, BidaskClub downgraded shares of ABIOMED from a “sell” rating to a “strong sell” rating in a report on Saturday, August 31st. Two research analysts have rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the stock. ABIOMED currently has a consensus rating of “Hold” and a consensus price target of $316.50.

In related news, COO David M. Weber sold 8,095 shares of the company’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $206.26, for a total value of $1,669,674.70. Following the sale, the chief operating officer now owns 132,913 shares of the company’s stock, valued at $27,414,635.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 3.40% of the company’s stock.

Shares of NASDAQ:ABMD traded down $0.10 on Friday, hitting $187.92. 10,547 shares of the company were exchanged, compared to its average volume of 443,144. The company’s 50 day moving average price is $205.53 and its two-hundred day moving average price is $260.78. ABIOMED, Inc. has a one year low of $180.00 and a one year high of $459.75. The firm has a market capitalization of $8.70 billion, a price-to-earnings ratio of 52.23, a PEG ratio of 1.70 and a beta of 0.45.

ABIOMED (NASDAQ:ABMD) last posted its earnings results on Thursday, August 1st. The medical equipment provider reported $1.00 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.01. The business had revenue of $207.70 million for the quarter, compared to analysts’ expectations of $210.96 million. ABIOMED had a net margin of 32.35% and a return on equity of 19.84%. The firm’s revenue for the quarter was up 15.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.95 earnings per share. As a group, equities analysts expect that ABIOMED, Inc. will post 4.28 EPS for the current year.

ABIOMED Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Recommended Story: Front-End Load

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.